嵌合抗原受体
医学
卵巢癌
免疫疗法
细胞疗法
T细胞受体
肿瘤科
癌症
T细胞
浆液性液体
癌症研究
内科学
免疫学
细胞
免疫系统
生物
遗传学
作者
Jessica Wu,Sudiksha Dand,Lachlan Doig,Anthony T. Papenfuss,Clare L. Scott,Gwo Yaw Ho,Joshua D. Ooi
标识
DOI:10.3389/fimmu.2021.672502
摘要
Ovarian cancer, in particularly high-grade serous ovarian cancer (HGSOC) and ovarian carcinosarcoma (OCS), are highly aggressive and deadly female cancers with limited treatment options. These tumors are generally unresponsive to immune check-point inhibitor (ICI) therapy and are referred to as immunologically "cold" tumors. Cell-based therapy, in particular, adoptive T-cell therapy, is an alternative immunotherapy option that has shown great potential, especially chimeric antigen receptor T cell (CAR-T) therapy in the treatment of hematologic malignancies. However, the efficacy of CAR-T therapy in solid tumors has been modest. This review explores the potential of another cell-based therapy, T-cell receptor therapy (TCR-T) as an alternate treatment option for immunological "cold" OC and OCS tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI